vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and OppFi Inc. (OPFI). Click either name above to swap in a different company.
OppFi Inc. is the larger business by last-quarter revenue ($85.6M vs $62.1M, roughly 1.4× Cytek Biosciences, Inc.). OppFi Inc. runs the higher net margin — 19.7% vs -70.9%, a 90.6% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs 5.9%). OppFi Inc. produced more free cash flow last quarter ($382.2M vs $-1.8M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 16.3%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
OppFi Inc. is a US-headquartered financial technology firm that provides responsible, accessible financial solutions including installment loans, credit-building tools and related support services to consumers underserved by traditional banking institutions, prioritizing fair terms to help users boost their long-term financial wellness.
CTKB vs OPFI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $85.6M |
| Net Profit | $-44.1M | $16.8M |
| Gross Margin | 52.9% | — |
| Operating Margin | -9.0% | 36.1% |
| Net Margin | -70.9% | 19.7% |
| Revenue YoY | 8.1% | 5.9% |
| Net Profit YoY | -557.1% | 400.3% |
| EPS (diluted) | — | $1.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $85.6M | ||
| Q3 25 | $52.3M | $104.6M | ||
| Q2 25 | $45.6M | $100.2M | ||
| Q1 25 | $41.5M | $90.8M | ||
| Q4 24 | $57.5M | $80.8M | ||
| Q3 24 | $51.5M | $91.2M | ||
| Q2 24 | $46.6M | $86.3M | ||
| Q1 24 | $44.9M | $63.2M |
| Q4 25 | $-44.1M | $16.8M | ||
| Q3 25 | $-5.5M | $41.6M | ||
| Q2 25 | $-5.6M | $-20.8M | ||
| Q1 25 | $-11.4M | $-11.4M | ||
| Q4 24 | $9.6M | $-5.6M | ||
| Q3 24 | $941.0K | $4.3M | ||
| Q2 24 | $-10.4M | $3.1M | ||
| Q1 24 | $-6.2M | $5.5M |
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — | ||
| Q1 24 | 51.3% | — |
| Q4 25 | -9.0% | 36.1% | ||
| Q3 25 | -17.6% | 46.3% | ||
| Q2 25 | -23.3% | 44.7% | ||
| Q1 25 | -36.1% | 46.8% | ||
| Q4 24 | 5.2% | 30.5% | ||
| Q3 24 | -8.2% | 38.5% | ||
| Q2 24 | -18.3% | 34.2% | ||
| Q1 24 | -23.9% | 8.4% |
| Q4 25 | -70.9% | 19.7% | ||
| Q3 25 | -10.5% | 39.8% | ||
| Q2 25 | -12.2% | -20.7% | ||
| Q1 25 | -27.5% | -12.5% | ||
| Q4 24 | 16.8% | -6.9% | ||
| Q3 24 | 1.8% | 4.7% | ||
| Q2 24 | -22.4% | 3.6% | ||
| Q1 24 | -13.8% | 8.8% |
| Q4 25 | — | $1.48 | ||
| Q3 25 | — | $0.77 | ||
| Q2 25 | — | $-0.78 | ||
| Q1 25 | — | $-0.48 | ||
| Q4 24 | — | $-0.11 | ||
| Q3 24 | — | $0.21 | ||
| Q2 24 | — | $0.16 | ||
| Q1 24 | — | $0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $49.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $58.5M |
| Total Assets | $461.5M | $754.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $49.5M | ||
| Q3 25 | $93.3M | $45.5M | ||
| Q2 25 | $75.5M | $45.2M | ||
| Q1 25 | $95.3M | $58.0M | ||
| Q4 24 | $98.7M | $61.3M | ||
| Q3 24 | $162.3M | $44.8M | ||
| Q2 24 | $177.9M | $46.6M | ||
| Q1 24 | $168.8M | $47.2M |
| Q4 25 | $341.7M | $58.5M | ||
| Q3 25 | $378.6M | $49.4M | ||
| Q2 25 | $377.6M | $13.4M | ||
| Q1 25 | $379.6M | $22.6M | ||
| Q4 24 | $395.7M | $32.8M | ||
| Q3 24 | $385.5M | $34.9M | ||
| Q2 24 | $389.1M | $18.6M | ||
| Q1 24 | $392.6M | $18.2M |
| Q4 25 | $461.5M | $754.1M | ||
| Q3 25 | $494.9M | $720.6M | ||
| Q2 25 | $493.3M | $673.4M | ||
| Q1 25 | $482.6M | $640.1M | ||
| Q4 24 | $499.5M | $641.2M | ||
| Q3 24 | $491.2M | $619.3M | ||
| Q2 24 | $483.7M | $573.1M | ||
| Q1 24 | $492.1M | $563.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $401.3M |
| Free Cash FlowOCF − Capex | $-1.8M | $382.2M |
| FCF MarginFCF / Revenue | -2.9% | 446.6% |
| Capex IntensityCapex / Revenue | 1.6% | 22.3% |
| Cash ConversionOCF / Net Profit | — | 23.82× |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | $652.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $401.3M | ||
| Q3 25 | $-3.9M | $105.1M | ||
| Q2 25 | $108.0K | $95.6M | ||
| Q1 25 | $-125.0K | $83.7M | ||
| Q4 24 | $2.0M | $323.8M | ||
| Q3 24 | $13.2M | $77.6M | ||
| Q2 24 | $6.2M | $77.3M | ||
| Q1 24 | $4.0M | $74.4M |
| Q4 25 | $-1.8M | $382.2M | ||
| Q3 25 | $-4.6M | $99.9M | ||
| Q2 25 | $-1.5M | $91.0M | ||
| Q1 25 | $-974.0K | $79.3M | ||
| Q4 24 | $1.1M | $310.8M | ||
| Q3 24 | $12.2M | $73.7M | ||
| Q2 24 | $5.2M | $74.7M | ||
| Q1 24 | $3.4M | $72.3M |
| Q4 25 | -2.9% | 446.6% | ||
| Q3 25 | -8.7% | 95.6% | ||
| Q2 25 | -3.2% | 90.8% | ||
| Q1 25 | -2.3% | 87.4% | ||
| Q4 24 | 1.9% | 384.6% | ||
| Q3 24 | 23.7% | 80.8% | ||
| Q2 24 | 11.0% | 86.6% | ||
| Q1 24 | 7.6% | 114.4% |
| Q4 25 | 1.6% | 22.3% | ||
| Q3 25 | 1.3% | 5.0% | ||
| Q2 25 | 3.5% | 4.6% | ||
| Q1 25 | 2.0% | 4.8% | ||
| Q4 24 | 1.6% | 16.1% | ||
| Q3 24 | 2.0% | 4.3% | ||
| Q2 24 | 2.3% | 3.0% | ||
| Q1 24 | 1.3% | 3.4% |
| Q4 25 | — | 23.82× | ||
| Q3 25 | — | 2.52× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | 18.19× | ||
| Q2 24 | — | 25.21× | ||
| Q1 24 | — | 13.44× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
OPFI
Segment breakdown not available.
